Document:

EX-10.34

 Exhibit 10.34 

HUMAN SERUM ALBUMIN INGREDIENT PURCHASE AND SALE AGREEMENT 

This Ingredient Purchase and Sale Agreement and its Exhibits (the “Agreement”) is made by and between [/*[CONFIDENTIAL TREATMENT
REQUESTED]*/] with principal offices at [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] (“Supplier”), and Ampio Pharmaceuticals., a Delaware corporation with principal offices at 5445 DTC Parkway, Suite 925 Greenwood Village, CO 80111
(“Customer”), and is made effective upon the date of last signature hereto (the “Effective Date”). Supplier and Customer are collectively referred to herein as “Parties”, or individually as a “Party”. 

WHEREAS, Customer wishes to purchase Albumin (Human) from Supplier (the “Products”) [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
for Albumin (Human) used for ingredient purposes (listed in Exhibit C); and 
 WHEREAS, Supplier wishes to supply the Products to
Customer [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] for Albumin (Human) used for ingredient purposes under the terms of this Agreement; 

NOW THEREFORE, in consideration of the foregoing promises and the mutual agreements herein and other valuable consideration, the
Parties agree as follows: 
  

	1.	PRODUCT SUPPLY 

1.1    Supply, Forecasting, and Use of Products. Subject to the terms and conditions of this Agreement, Supplier
hereby agrees to sell to Customer the quantities of Products on the shipment schedule specified in Exhibit A hereto [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]. Supplier shall remain fully liable for Supplier’s [/*[CONFIDENTIAL TREATMENT
REQUESTED]*/] performance or failure to perform [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]. 
Each [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] Supplier shall provide all Products subject to the minimum 
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
purchase commitment detailed below, from as few whole manufacturing lots as possible. Customer shall provide a [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] forecast detailing the quantity of Products expected to be delivered in the relevant
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/], as well as requested delivery dates. [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] and Customer will mutually agree on the actual ship and delivery dates. Customer agrees that it will use the Products for
manufacturing purposes only. Customer further agrees that it will comply with all laws and regulations applicable to the storage, use, and disposal of the Products. Customer shall timely file a complete application with the US FDA and obtain
authorization for use of the Products as a raw material in the manufacture of its products, as well as any other governmental agency that may have jurisdiction over the use of the Product as an ingredient. Upon written request customer shall provide
Supplier prompt written notice of each agency which has approved the Products for use as an ingredient. Supplier shall notify Customer of any changes to the specifications for the Product. 

1.2    Inspection and Acceptance. Customer shall inspect each shipment of Products within ten (10) business
days of receipt. Customer may also request to inspect sample units from each shipment prior to shipping entire shipment. No testing, inspection or other action by Customer will relieve Supplier of its obligations to replace defective or
non-conforming Product which, upon subsequent testing, inspection or use, proves to be defective or nonconforming. Customer shall promptly notify [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] of any nonconformity of the Product with the applicable USP or
EP Certificate of Analysis, damage or short shipment occasioned by [/*[CONFIDENTIAL TREATMENT 

 
REQUESTED]*/] or occurring in transit. In the event of any such damage, nonconformity, or short shipment, Customer shall promptly contact [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]. Supplier will
replace such damaged, nonconforming, or missing Product at no additional cost to Customer, and Supplier will use commercially reasonable efforts to ship any replacement Products 
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] within two (2) weeks
or sooner. 
 1.3    Expiration of Product. Each shipment of Products shall provide a minimum shelf life of twelve
(12) months measured from Customer’s date of receipt of Products. 
 1.4    Shipment of Products and Risk of
Loss. [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] will ship Products on a 
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] basis to the destination designated by Customer and shipped in compliance with Customer’s shipping requirements, as detailed
in Exhibit A. 
 1.5    Prices, Payment, and Minimum/Maximum [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] Purchase
Commitment. The Price and Minimum [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] Purchase Commitment for Products are detailed in Exhibit B. Payment terms between [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] and Customer shall be negotiated directly
between Customer and [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]. However, payments terms shall be no less than 30 days, net 31 upon Customer’s receipt of invoice from [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]. Supplier will provide a maximum
of [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] per [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] period and will honor all orders placed by Customer in compliance with the provisions of this Agreement. Should larger volumes be required, a [/*[CONFIDENTIAL
TREATMENT REQUESTED]*/] lead time for planning purposes is required. 
 1.6    Documentation. A USP and EP
Certificate of Analysis and batch release OMCL certificate will be provided for each lot. 
  

	2.	REPRESENTATIONS AND WARRANTIES 

 Supplier hereby
represents and warrants that the Products will be supplied in accordance with the terms and conditions hereunder and will be compliant with the applicable USP material data sheets providing reference standards or EP Certificate of Analysis and
acknowledges that it will notify customer of any significant changes SUPPLIER MAKES NO REPRESENTATIONS NOR EXTENDS ANY WARRANTIES OR CONDITIONS OF ANY KIND, EITHER EXPRESS OR IMPLIED, WITH RESPECT TO THE PRODUCTS, INCLUDING, BUT NOT LIMITED TO,
WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. 
  

	3.	CONFIDENTIALITY  

 The Parties, together with their
employees, consultants, contractors, and agents shall keep confidential and shall not, directly or indirectly, disclose, publish, or use for the benefit of any third party or itself, except in carrying out the obligations under this Agreement, any
Confidential Information (as defined below) of the other Party without first having obtained the other Party’s written consent to such disclosure or use. “Confidential Information” shall include, but not be limited to, data, know-how,
analyses, processes, manufacturing protocols, standard operating procedures, compilations, forecasts, studies, raw materials, research and development information, sales data, pricing information, customer lists, production methods, records and
other documents and other similar and related information concerning the disclosing Party’s business, financial condition, operations, and technical expertise and know-how. This restriction shall not apply for Confidential Information which:

 (a)    is, or becomes public knowledge without fault on the part of the receiving Party or its employees, consultants,
contractors, or agents; or 

  
 2 

 (b)    the receiving Party can establish by competent proof, was in the
receiving Party’s possession at the time of disclosure and was not acquired, directly or indirectly from the disclosing Party; or 

(c)    the receiving Party receives from a third party, provided that such Confidential Information was not obtained
directly or indirectly from the disclosing Party; or 
 (d)    is required to be disclosed by order of a court of
competent jurisdiction or governmental authority, but only to the extent of and for the purpose of such order, and provided that the receiving Party has timely informed the disclosing Party of all such proceedings so that the disclosing Party may
attempt to limit such disclosure of confidentiality; or 
 (e)    is used by Customer as part of its regulatory
submission to the regulatory authority from which Customer is seeking approval for the use of the Products as an ingredient and written notice that such application has been or will be submitted is provided to Supplier. The terms of this
confidentiality provision shall survive any termination or expiration of this Agreement. 
  

	4.	INDEMNIFICATION AND LIMITATION ON LIABILITY 

4.1    Indemnification by Supplier. Supplier shall indemnify, defend and hold harmless Customer and its affiliates
and the directors, officers, employees, agents and counsel of the foregoing from and against any and all liabilities, damages, losses, costs or expenses (including reasonable attorneys’ and professional fees and other expenses of litigation
and/or arbitration) instituted by third parties (collectively, “Claims”) for (i) any defect in the Products, including that which results in personal injury or death, arising out of or in connection with, or as a result of,
Supplier’s breach of a term of this Agreement, (ii) infringement of such third party’s patent rights as a result of Customer’s use of the Product set forth herein, (iii) and/or negligent or willful misconduct of Supplier in
connection with the performance of its obligations under this Agreement, except to the extent caused by the negligence or willful misconduct of the Customer, its agents, assigns or contractors or in the event it or its agents, assigns or contractors
are claimed to have breached any of the national, regional or local laws or administrative codes of the country, state or territory where the product was sold. 

4.2    Indemnification by Customer. Customer shall indemnify, defend and hold harmless Supplier and its affiliates
and the directors, officers, employees, agents and counsel of the foregoing from and against any and all liabilities, damages, losses, liens, costs or expenses (including reasonable attorneys’ and professional fees and other expenses of
litigation and/or arbitration) arising out of or in connection with, or as a result of, any use of the Products. This shall include actions instituted by third parties (collectively, “Claims”) for personal injury, arising out of or in
connection with, or as a result of, any use or marketing of the Products, breach of Customer’s obligations hereunder, or the negligence or willful misconduct of Customer in connection with the performance of its obligations under this
Agreement, except to the extent caused by the negligence or willful misconduct of Supplier, and its agents, assigns or contractors. 

4.3    Indemnification Procedure. Promptly after learning of the occurrence of any event which may give rise to a
right of indemnification specified in this Section 4 the indemnitee hereunder shall give written notice of such matter to the indemnitor. The indemnitee shall cooperate with the indemnitor in the negotiation, compromise and defense of any such
matter. The indemnitor shall be in charge of and control such negotiations, compromise and defense and shall have the right to select counsel with respect thereto, 

  
 3 

 
provided that the indemnitor shall promptly notify the indemnitee of all developments in the matter. Without releasing any liability, obligation or undertaking of the indemnitor, the indemnitee
may, at its sole discretion and expense, participate in any such proceedings through counsel of its own choosing. The indemnitor may not, without the prior written consent of the indemnitee, enter into any compromise or settlement of any such matter
the terms of which (i) are not confidential, (ii) in any way admit the indemnitee’s liability or (iii) require the indemnitee to take or refrain from taking any action or make any payment; and the indemnitee shall not be bound by
any such compromise or settlement absent its prior consent. 
 4.4    No Indirect Damages. Notwithstanding any
other provision of this Agreement to the contrary, neither Party shall not be liable hereunder to the other Party or any other party for any loss of use, interruption of business, or any other indirect, special, incidental, exemplary, punitive or
consequential damages of any kind (including lost profits) regardless of the form of action, whether contract, tort (including negligence), strict product liability or otherwise, even if the aggrieved party has been advised of the possibility of
such damages. 
 4.5    Limitation on Liability. Other than with respect to a Party’s indemnification
obligations, each Party’s maximum liability to the other Party arising out of this Agreement shall be limited to the monetary amount actually paid or payable hereunder by Customer under this Agreement. 

4.6    TERM AND TERMINATION 

4.7    Term. The term of this Agreement will commence on the Effective Date and remain in effect through and
including the last calendar day of the fifth (5th) year after the Effective Date. As an example, if the Effective Date of this Agreement is September 1, 2013, then the termination date
of the Agreement would be December 31, 2018. Upon mutual, written agreement between the Supplier and Customer, Supplier and Customer reserve the right to, upon completion of the second full contract year, extend this Agreement for an additional
five years subject to the provisions of this Agreement. 
 4.8    Termination. Either Party may terminate this
Agreement upon the breach of a material term of this Agreement by the other Party if such Party fails to cure the material breach within thirty (30) days of receiving written notice of such material breach from the non-defaulting Party.
Supplier may terminate this Agreement for any reason upon three hundred sixty-five (365) days prior written notice to Customer. Additionally, Customer may terminate this Agreement for any reason upon one hundred twenty (120) days prior
written notice to Supplier. Except as provided below, if Customer terminates this Agreement without cause, Customer shall 
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] in which the notice to Supplier is received by Supplier. If the US FDA or any
other regulatory body to which Customer has applied declines to approve Customer’s final application for use of the Products as an ingredient and Customer terminates this Agreement without cause, then Customer shall not be required to
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]. Similarly, if the US FDA or similar regulatory body outside the US delays approval beyond the anticipated timeframe specified in Exhibit A, Supplier agrees to [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]. 

4.9    Effect of Breach or Termination. Termination of this Agreement for any reason shall not release any Party
hereto from any liability which, at the time of such termination, has already accrued to the other Party or which is attributable to a period prior to such termination nor preclude either Party from pursuing all rights and remedies it may have
hereunder or at law or in equity with respect to any breach of this Agreement. Upon any termination of this Agreement, each Party shall promptly return to the other Party all Confidential Information received from such other Party (except one copy
of which may be retained for archival purposes). 

  
 4 

 4.10    Survival. Sections 1.2, 1.3, 1.4, 1.6 (each, until satisfied),
and Articles 2, 3 and 4, Section, and Articles 6 and shall survive the expiration or termination of this Agreement for any reason. 
  

	5.	TRADEMARKS  

 Customer shall have no right or license in the
trademarks of Supplier or any of its affiliates. As between Customer and Supplier, all right, title and interest in the Supplier trademarks shall belong exclusively to Supplier or its affiliate, and all uses of the Supplier trademarks shall inure to
the benefit of Supplier or its affiliate for all purposes. 
  

	6.	MISCELLANEOUS 

6.1    Governing Law; Jurisdiction. This Agreement, and any disputes arising out of or in connection with this
Agreement, shall be governed by and construed in accordance with the laws of New York State, excluding its rules governing conflicts of laws. The sole and exclusive venue for all disputes arising out of or relating in any way to this Agreement shall
be in New York State and United States Federal Courts sitting in New York County, New York. The Parties consent to the personal jurisdiction and venue of such courts and further consent that any process, notice of motion or other application to
either such court or a judge thereof may be served outside New York State by registered or certified mail or by personal service, provided that a reasonable time for appearance is allowed. 

6.2    Notices. All notices and other communications hereunder or in connection herewith (except for purchase
orders) shall be validly given or made if in writing and shall be effective either (a) when delivered in person to the other Party, or (b) two (2) days after being addressed to the Party at the address specified below, and sent by
nationally recognized express courier service. Unless and until subsequently changed by notice given in accordance with this Section 7, the addresses of the Parties for purposes of all notices and communications hereunder shall be as follows:

  

			
	If to Supplier:	  	If to Customer:
		
	 [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]

[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]

[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]

[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]

[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
	  	 Josh Disbrow,
 Chief Operating Officer

Ampio Pharmaceuticals, Inc
 5445 DTC Parkway, Suite 925

Greenwood Village, CO 80111

		
	 Copy:

Susanna S. Piller, Esq.

Stafford, Piller, Murnane, Plimpton, Kelleher & Trombley PLLC

One Cumberland Avenue

P.O. Box 2947

Plattsburgh, NY 12901

(518) 561-4400
	  	 Copy:
 Stephen M. Davis

Goodwin Procter LLP
 The New York Times Building

620 Eighth Avenue
 New York, NY 10018

T: 212-813-8804

  
 5 

 6.3    Insurance. Supplier and Customer each agree to maintain and
keep in full force and effect during the entire term of this Agreement, at their own expenses and costs, general liability insurance covering their respective activities and obligations contemplated under this Agreement, in the minimum amount of
$[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]. Upon request, each Party shall furnish the other Party with a certificate of insurance evidencing such coverage. 

6.4    Force Majeure. Any delay or failure in the performance of any of the duties (except the payment of money) or
obligations of any Party hereto shall not be considered a breach of this Agreement and the time required for performance shall be extended for a period equal to the period of such delay, provided that such delay has been caused by or is the result
of any acts of God; acts of the public enemy; insurrections; riots; embargoes; fires; explosions; product recalls plant failures; actions or decisions by governmental authorities or courts of law that limits or restricts the production or
distribution of the Products; floods; energy; failure of Supplier’s suppliers [/*[CONFIDENTIAL TREATMENT REQUESTED]*/], or other causes beyond the control and without the fault or negligence of the Party so affected. The Party so affected shall
provide the other Party with full particulars thereof as soon as it becomes aware of the same (including its best estimate of the likely extent and duration of the interference with its activities), and will use its reasonable best efforts to
overcome the difficulties created thereby and to resume performance of its obligations as soon as practicable. If the performance of any obligation under this Agreement is delayed owing to a force majeure for any continuous period of more than two
(2) months, the Parties hereto shall consult with respect to an equitable solution, including the possible termination of this Agreement. 

6.5    Waiver. Neither Party may waive or release any of its rights or interests in this Agreement except in
writing. The failure of either Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or
condition. 
 6.6    Assignability. This Agreement shall be binding on and inure solely to the benefit of the
Parties hereto and their respective successors and assigns; provided however, this Agreement and the rights and obligations hereunder may not be assigned without the prior written consent of the other Party, which shall not be unreasonably withheld,
and any such attempt at assignment shall be void and unenforceable, except that either party may assign this Agreement without consent to a successor-in-interest pursuant to a sale or transfer of all or substantially all of the assets of the
business to which this Agreement pertains. 
 6.7    Independent Contractor. All Parties are independent
contractors under this Agreement. Nothing contained in this Agreement is intended nor is to be construed so as to constitute Customer or Suppliers as partners or joint venturers with respect to this Agreement. Neither Party shall have any express or
implied right or authority to assume or create any obligations on behalf of or in the name of the other Party or to bind the other Party to any other contract, agreement, or undertaking with any third party. 

6.8    Publicity. No Party shall issue any press release or other publicity in connection with this Agreement
without the other Party’s prior written consent. No Party shall publicize or otherwise disclose the terms of the Agreement without the prior written approval of the other Party, unless required by law. If disclosure is required by law, the
relevant Party shall notify the other Party in writing thirty (30) days prior to the date of disclosure and shall consult on the necessity and content of the disclosure. Supplier acknowledges that Customer may need to disclose Supplier’s
PMF and CTD Modules 2 and 3 to regulatory authorities as part of its application to seek approval for use of the Products as an ingredient, and that such disclosures will be subject to notification of Supplier, but not prior written approval
requirement. Neither Party shall use the names of the other Party, its officers, employees and agents for purposes of any public commercial activity without such other Party’s prior written consent. 

  
 6 

 6.9      Severability. In the event that any provision of
this Agreement becomes or is declared by a court of competent jurisdiction to be illegal, unenforceable, or void, this Agreement shall continue in full force and effect without said provision. 

6.10    Complete Agreement. This Agreement with its Exhibits, when executed, shall constitute the entire Agreement,
both written and oral, between the Parties with respect to the subject matter hereof, and that all prior agreements respecting the subject matter hereof, either written or oral, expressed or implied, are merged and canceled, and are null and void
and of no effect. No amendment or change hereof or addition hereto shall be effective or binding on either of the Parties hereto unless reduced to writing and duly executed on behalf of both Parties. To the extent there is a conflict or
inconsistency between the body of this Agreement and any Exhibit, the body of this Agreement shall prevail. 

6.11    Headings. The captions to the several sections and articles hereof are not a part of this Agreement, but are
included merely for convenience of reference only and shall not affect its meaning or interpretation. 

6.12    Counterparts. This Agreement may be executed in counterparts, or facsimile versions, each of which shall be
deemed to be an original, and both together shall be deemed to be one and the same agreement. 
 SIGNATURES BEGIN ON NEXT PAGE 

  
 7 

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed by
their authorized representatives as of the Effective Date. 
  

									
	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]	 		 	Ampio Pharmaceuticals, Inc.
					
	By:	 	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]	 		 	By:	 	/s/ Michael Macaluso
					
	Name:	 	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]	 		 	Name:	 	Michael Macaluso
					
	Title:	 	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]	 		 	Title: 	 	CEO
					
	Date:	 	10/10/2013	 		 	Date:	 	9/27/2013

  
 8 

 EXHIBIT A 

QUANTITIES OF PRODUCTS 
 Albumin
(Human): 
 Purchases to be shipped to the address listed below, pursuant to [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]: 

Ampio Pharmaceuticals 
 Ampio Pharmaceuticals, Inc 

5445 DTC Parkway, Suite 925 
 Greenwood Village, CO 80111 

Shipping Instructions: To Be Provided by Customer prior to initial shipment 

MINIMUM [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] PURCHASE COMMITMENT 

(MAC) 
  

			
	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]	  	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]	  	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]	  	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]	  	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]	  	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]	  	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]

 [Note: Customer anticipates approval in the [/*[CONFIDENTIAL
TREATMENT REQUESTED]*/] time frame.] 
 Customer shall submit, to [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] Supplier [/*[CONFIDENTIAL TREATMENT
REQUESTED]*/], a [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] forecast of volumes, which forecasts shall be due by the first business day of every 

 
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]. The first forecast shall be due starting with the beginning of the first full 
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] of the term of this Agreement.
Once each forecast is submitted, the 
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] forecast volumes will become binding purchase obligations by the customer and binding supply obligations for the Supplier for those [/*[CONFIDENTIAL TREATMENT
REQUESTED]*/] respectively. If Customer does not place an order and take delivery for those quantities or only orders and takes delivery for a part of those quantities, the [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] may supply the shortfall to
Customer and invoice Customer for up to the full volumes for those [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]. 
 For each successive forecast, the prior
forecast’s volumes in [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] through 
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] shall move up and become the forecast of [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] through [/*[CONFIDENTIAL TREATMENT
REQUESTED]*/] in the new forecast and a new volume shall be entered for [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]. As the prior forecast’s [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] volume is already binding, it will move unchanged into the new
forecast’s [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] forecast. As the prior forecast’s [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] volume is moved into the new forecast’s [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] forecast, it may be
changed at that time up to [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] in [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] from the prior forecast. As the prior forecast’s [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] volume is moved into the new
forecast’s 
[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] forecast, it may be changed at that time up to [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] in [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] from the prior forecast. 

Any deviation or exception to the above shall be at the sole discretion of the Supplier and shall be agreed to in writing. 

 EXHIBIT B 

PRICES FOR PRODUCTS 
  

					
	Strength	 	Bottle size	 	Price
	 [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
	 	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]	 	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]*

 *Price includes [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]. Supplier will notify Customer of any material changes in the
foregoing [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]. 
 Price does include [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]. 

Bill to: 
 Ampio Pharmaceuticals 

Ampio Pharmaceuticals, Inc 
 5445 DTC Parkway, Suite 925 

Greenwood Village, CO 80111 

 EXHIBIT C 

[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] 

[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] 
 [/*[CONFIDENTIAL
TREATMENT REQUESTED]*/] 
 [/*[CONFIDENTIAL TREATMENT REQUESTED]*/] 

[/*[CONFIDENTIAL TREATMENT REQUESTED]*/] 
 [/*[CONFIDENTIAL
TREATMENT REQUESTED]*/] 
  

			
	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
		
	By:	 	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
		
	Name:	 	[/*[CONFIDENTIAL TREATMENT REQUESTED]*/]
		
	Title:	 	 [/*[CONFIDENTIAL TREATMENT REQUESTED]*/]

		
	Date:	 	10/7/2013Form of Executive Agreement for certain executive officers

 Exhibit 10.1 

Schedule Identifying Material Details of 

Executive Agreements Substantially Similar to Exhibit 10.3 to Huntington’s 

Current Report on Form 8-K dated November 28, 2012 
  

			
	 Name
	 	 Effective Date

	 David S. Anderson
	 	June 20, 2013
	 Richard A. Cheap
	 	November 28, 2012
	 James E. Dunlap
	 	November 28, 2012
	 Paul G. Heller
	 	November 28, 2012
	 Helga S. Houston
	 	November 28, 2012
	 Mary W. Navarro
	 	November 28, 2012
	 Daniel J. Neumeyer
	 	November 28, 2012
	 Keith D. Sanders
	 	November 28, 2012
	 Nicholas G. Stanutz
	 	November 28, 2012
	 Mark E. Thompson
	 	November 28, 2012

 Schedule Identifying Material Details of 

Executive Agreements Substantially Similar to Exhibit 10.2 to Huntington’s 

Quarterly Report on Form 10-Q for the Period Ended June 30, 2013. 
  

			
	 Name
	 	 Effective Date

	 Barbara H. Benham
	 	July 16, 2013

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00226-of-00352.parquet"}]]